Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry

S. Masson, M. Gorini, M. Salio, D. Lucci, R. Latini, A. P. Maggioni

Research output: Contribution to journalArticle

Abstract

Background. Activation of neuroendocrine factors plays a major role in the pathophysiology and progression of heart failure. The aim of the present study was 1) to assess the clinical correlates of elevated plasma natriuretic peptides [atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)] and Big endothelin-1 in a population of 180 ambulatory patients from the Italian registry of heart failure (Italian Network on Congestive Heart Failure, IN-CHF) in 22 clinical centers, 2) to assess the within-patient variability of plasma BNP concentration, and 3) to evaluate the analytical agreement for BNP determination between a core laboratory and local sites. Methods. ANP and BNP were measured with specific immunoradiometric methods, Big endothelin-1 with an enzyme immunoassay. Results. Elevated BNP was associated with severe mitral valve regurgitation (odds ratio 8.546, 95% confidence interval 1.879-38.510, p = 0.0052); high circulating concentrations of ANP and BNP were found in older patients, and in patients with higher NYHA functional class or reduced left ventricular ejection fraction. Elevated plasma concentration of Big endothelin-1 was a strong and independent predictor of atrial fibrillation (odds ratio 4.001, 95% confidence interval 1.531-10.454, p = 0.0047). Plasma concentration of BNP was reasonably stable at 3-month interval in patients with mild-to-moderate heart failure (mean between-visit difference -1.5 ± 45 pg/ml, n = 96). There was a satisfactory analytical agreement between the central laboratory and sites, over a broad range of concentrations (2-1133 pg/ml, n = 283) with a slope for the best line fitted by linear regression of 1.09 (r2 = 0.96). Conclusions. BNP assay may become an appropriate tool for routine clinical practice in patients with congestive heart failure.

Original languageEnglish
Pages (from-to)282-288
Number of pages7
JournalItalian Heart Journal
Volume1
Issue number4
Publication statusPublished - 2000

Fingerprint

Natriuretic Peptides
Brain Natriuretic Peptide
Endothelin-1
Registries
Heart Failure
Population
Atrial Natriuretic Factor
Odds Ratio
Confidence Intervals
Mitral Valve Insufficiency
Immunoenzyme Techniques
Stroke Volume
Atrial Fibrillation
Linear Models

Keywords

  • Atrial natriuretic peptide
  • Big endothelin-1
  • Brain natriuretic peptide
  • Heart failure
  • Hormones
  • Natriuretic peptides

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{6659ed4e5bd04456bdccdac7e0686bc6,
title = "Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry",
abstract = "Background. Activation of neuroendocrine factors plays a major role in the pathophysiology and progression of heart failure. The aim of the present study was 1) to assess the clinical correlates of elevated plasma natriuretic peptides [atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)] and Big endothelin-1 in a population of 180 ambulatory patients from the Italian registry of heart failure (Italian Network on Congestive Heart Failure, IN-CHF) in 22 clinical centers, 2) to assess the within-patient variability of plasma BNP concentration, and 3) to evaluate the analytical agreement for BNP determination between a core laboratory and local sites. Methods. ANP and BNP were measured with specific immunoradiometric methods, Big endothelin-1 with an enzyme immunoassay. Results. Elevated BNP was associated with severe mitral valve regurgitation (odds ratio 8.546, 95{\%} confidence interval 1.879-38.510, p = 0.0052); high circulating concentrations of ANP and BNP were found in older patients, and in patients with higher NYHA functional class or reduced left ventricular ejection fraction. Elevated plasma concentration of Big endothelin-1 was a strong and independent predictor of atrial fibrillation (odds ratio 4.001, 95{\%} confidence interval 1.531-10.454, p = 0.0047). Plasma concentration of BNP was reasonably stable at 3-month interval in patients with mild-to-moderate heart failure (mean between-visit difference -1.5 ± 45 pg/ml, n = 96). There was a satisfactory analytical agreement between the central laboratory and sites, over a broad range of concentrations (2-1133 pg/ml, n = 283) with a slope for the best line fitted by linear regression of 1.09 (r2 = 0.96). Conclusions. BNP assay may become an appropriate tool for routine clinical practice in patients with congestive heart failure.",
keywords = "Atrial natriuretic peptide, Big endothelin-1, Brain natriuretic peptide, Heart failure, Hormones, Natriuretic peptides",
author = "S. Masson and M. Gorini and M. Salio and D. Lucci and R. Latini and Maggioni, {A. P.}",
year = "2000",
language = "English",
volume = "1",
pages = "282--288",
journal = "Italian Heart Journal",
issn = "1129-471X",
publisher = "Societa Italiana di Cardiologia",
number = "4",

}

TY - JOUR

T1 - Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry

AU - Masson, S.

AU - Gorini, M.

AU - Salio, M.

AU - Lucci, D.

AU - Latini, R.

AU - Maggioni, A. P.

PY - 2000

Y1 - 2000

N2 - Background. Activation of neuroendocrine factors plays a major role in the pathophysiology and progression of heart failure. The aim of the present study was 1) to assess the clinical correlates of elevated plasma natriuretic peptides [atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)] and Big endothelin-1 in a population of 180 ambulatory patients from the Italian registry of heart failure (Italian Network on Congestive Heart Failure, IN-CHF) in 22 clinical centers, 2) to assess the within-patient variability of plasma BNP concentration, and 3) to evaluate the analytical agreement for BNP determination between a core laboratory and local sites. Methods. ANP and BNP were measured with specific immunoradiometric methods, Big endothelin-1 with an enzyme immunoassay. Results. Elevated BNP was associated with severe mitral valve regurgitation (odds ratio 8.546, 95% confidence interval 1.879-38.510, p = 0.0052); high circulating concentrations of ANP and BNP were found in older patients, and in patients with higher NYHA functional class or reduced left ventricular ejection fraction. Elevated plasma concentration of Big endothelin-1 was a strong and independent predictor of atrial fibrillation (odds ratio 4.001, 95% confidence interval 1.531-10.454, p = 0.0047). Plasma concentration of BNP was reasonably stable at 3-month interval in patients with mild-to-moderate heart failure (mean between-visit difference -1.5 ± 45 pg/ml, n = 96). There was a satisfactory analytical agreement between the central laboratory and sites, over a broad range of concentrations (2-1133 pg/ml, n = 283) with a slope for the best line fitted by linear regression of 1.09 (r2 = 0.96). Conclusions. BNP assay may become an appropriate tool for routine clinical practice in patients with congestive heart failure.

AB - Background. Activation of neuroendocrine factors plays a major role in the pathophysiology and progression of heart failure. The aim of the present study was 1) to assess the clinical correlates of elevated plasma natriuretic peptides [atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)] and Big endothelin-1 in a population of 180 ambulatory patients from the Italian registry of heart failure (Italian Network on Congestive Heart Failure, IN-CHF) in 22 clinical centers, 2) to assess the within-patient variability of plasma BNP concentration, and 3) to evaluate the analytical agreement for BNP determination between a core laboratory and local sites. Methods. ANP and BNP were measured with specific immunoradiometric methods, Big endothelin-1 with an enzyme immunoassay. Results. Elevated BNP was associated with severe mitral valve regurgitation (odds ratio 8.546, 95% confidence interval 1.879-38.510, p = 0.0052); high circulating concentrations of ANP and BNP were found in older patients, and in patients with higher NYHA functional class or reduced left ventricular ejection fraction. Elevated plasma concentration of Big endothelin-1 was a strong and independent predictor of atrial fibrillation (odds ratio 4.001, 95% confidence interval 1.531-10.454, p = 0.0047). Plasma concentration of BNP was reasonably stable at 3-month interval in patients with mild-to-moderate heart failure (mean between-visit difference -1.5 ± 45 pg/ml, n = 96). There was a satisfactory analytical agreement between the central laboratory and sites, over a broad range of concentrations (2-1133 pg/ml, n = 283) with a slope for the best line fitted by linear regression of 1.09 (r2 = 0.96). Conclusions. BNP assay may become an appropriate tool for routine clinical practice in patients with congestive heart failure.

KW - Atrial natriuretic peptide

KW - Big endothelin-1

KW - Brain natriuretic peptide

KW - Heart failure

KW - Hormones

KW - Natriuretic peptides

UR - http://www.scopus.com/inward/record.url?scp=0033781114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033781114&partnerID=8YFLogxK

M3 - Article

C2 - 10824729

AN - SCOPUS:0033781114

VL - 1

SP - 282

EP - 288

JO - Italian Heart Journal

JF - Italian Heart Journal

SN - 1129-471X

IS - 4

ER -